Epcoritamab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HIRA (South Korea) and NICE (England), among others, recommended or restricted epcoritamab, while DMC (Denmark), HAS (France) and ZIN (Netherlands) did not recommend it.
The record spans 2.7 years, opening at CHUIKYO (Japan) on 15 Nov 2023 and running to 2026.
AOTMIT (Poland) changed its position: restricted on 29 Apr 2024, not recommended by 29 Aug 2025.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 22 of 23 records date from 2023 or later.
6 distinct indication wordings are recorded for epcoritamab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess epcoritamab, on 15 Nov 2023; PHARMAC (New Zealand) did not open a file until 17 Mar 2026 — a moderate spread of 2.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 22 dated records fall in 2024 alone.
7 of the 14 agencies here assessed epcoritamab more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
epcoritamab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for epcoritamab reads 6 recommended, 6 not recommended, 3 no benefit and 2 appraised, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 17 Mar 2026 | Diffuse large B-cell lymphoma (DLBCL), relapsed/refractory (R/R), 3rd line or later | PTAC advice: High | source |
| NICE (England) | 11 Mar 2026 | NICE TA1139 | published appraisal | source |
| AWMSG (Wales) | 11 Mar 2026 | Treatment of relapsed or refractory follicular lymphoma after 2 or more systemic treatments | excluded, NICE appraised | source |
| HIRA (South Korea) | 4 Dec 2025 | 두 가지 이상의 전신 치료 후 재발성 또는 불응성 미만성 거대 B 세포 림프종 (diffuse large B-cell lymphoma, DLBCL) 성인 환자 (18 세 이상 ) 의 치료 | reimbursement appropriate | source |
| AOTMIT (Poland) | 29 Aug 2025 | programu lekowego „Leczenie chorych na chłoniaki B-komórkowe (ICD-10: C82, C83, C85) | not recommended | source |
18 further decisions for epcoritamab, across 12 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 17 further source documents.
Related molecules
- polatuzumab vedotin — divergent outcome (recommended vs not recommended) on a shared indication
- loncastuximab tesirine — divergent outcome (recommended vs not recommended) on a shared indication
- selinexor — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
Coverage: 23 decisions for epcoritamab from 14 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.